High Profile Clinical Trials 2023

High Profile Clinical Trials 2023

Today's High-Profile Clinical Trials

Clinical trials are constantly testing the boundaries of scientific breakthroughs, and it is always exciting to see the next stage of advancement. Collected below are three ongoing and upcoming clinical trials, along with an explanation of how they could change healthcare.

A New Alzheimer's Drug

Alzheimer's is one disease that has been stumping scientists for decades as they attempt to better understand what triggers the disease and what fuels its progression.

Currently, there is no cure for Alzheimer's, only treatments that slow disease progression. However, an upcoming clinical trial is investigating CT1812, a potential therapy to prevent and treat amyloid beta (Aß) oligomer-induced membrane trafficking deficits, which have been linked with early-onset Alzheimer's disease.

An upcoming clinical trial evaluating the safety and efficacy of CT1812 in individuals with Mild to Moderate Alzheimer's Disease and will use the drug CT1812 or placebo in its phase 2 trial, which will last approximately 6 months and will recruit 144 participants. Participants will be given either 100 mg or 300 mg of CT1812 or a placebo, administered once a day through oral applications.

CT1812 targets Aß oligomers through a novel mechanism and is the first selective sigma-2 receptor antagonist to reach clinical trials. Past trials have shown its ability to displace Aß oligomers bound to neuronal receptors, which can modify Alzheimer's disease mechanisms. The researchers hope to see that administration of CT1812 may prevent further neurodegeneration in Alzheimer's disease patients.

View other clinical trials that are recruiting participants: Alzheimer's Clinical Trials.

A Treatment for Triple Negative Breast Cancer

Many clinical trials surrounding breast cancer are currently ongoing, including new treatment options, improved screening methods, and better ways to raise awareness for one of the most common cancers in women.

One clinical trial shows promise in addressing triple negative breast cancer , which is challenging to treat since it does not express some of the receptors frequently found on breast cancer cells (i.e., estrogen, progesterone, HER2). This makes treatment much more difficult, as there are fewer things for treatment to target.

A phase 2 clinical trial is currently evaluating the safety and effectiveness of a combination treatment for metastatic triple negative breast cancer utilizing niraparib, dostarlimab, and radiation therapy.

Niraparib is a PARP inhibitor, blocking DNA repair and preventing cancer cells from repairing their damaged genetic code. While it has not yet been approved for metastatic triple-negative breast cancer, it has been approved for other uses. Dosterlimab is involved in immunotherapy and inhibits a protein called PD-1, which is responsible for shutting down immune responses that recognize and destroy cancer cells. It has not yet been FDA approved for any disease.

Participants in this trial will receive the drugs for 2 years, although they will stop the drugs if their triple-negative breast cancer worsens. All participants will then receive follow-ups for 5 years. It is estimated that 32 participants will be included in the study. The researchers hope that this treatment combination will result in improved anti-cancer immune responses and better tumor control.

View other clinical trials that are recruiting participants: Breast Cancer Clinical Trials .

Alternative Treatments for Depression

Other upcoming clinical trials are not investigating medication effectiveness but the ability of a new treatment modality to treat a health condition.

A clinical trial for individuals diagnosed with major depressive disorder (MDD) is testing a treatment using non-invasive transcranial direct current stimulation (tDCS), which is increasing in use as a treatment for depressive disorders.

The clinical trial is recruiting 100 patients per group, and they will undergo treatment with tDCS or sham tDCS for 20-minute sessions spread over the course of 12 days. The study aims to determine the feasibility and effectiveness of the treatment by measuring regional cerebral blood flow and administering a series of neurological tests. Researchers hope this will offer a new treatment option for patients with MDD.

View other clinical trials that are recruiting participants: Depression Clinical Trials .

The Exciting Promise of Clinical Trials

From curing a disease to offering at-home treatment options, clinical trials push the limits of healthcare, always with an end goal of improving patient health. Additionally, clinical trials offer the chance to try new treatments for broad or specific populations, allowing you to benefit from the advancements of medicine first-hand.

To find clinical trials near you click the button below to begin your search:

Search Clinical Trials